6070-74-2

Upstream product

• 531539-33-0 (2S,3S)-1-(benzyloxycarbonyl)-3-ethyl-glutamic acid 
• 98-79-3 L-Pyroglutamic acid 
• 531539-21-6 (2S)-5-oxo-pyrrolidine-2-carboxylic acid 3-methyl-oxetan-3-ylmethyl ester 
• 531539-23-8 (2S)-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-5-oxo-2,5-dihydro-pyrrole-1-carboxylic acid benzyl ester 
• 531539-18-1 (2S)-1-benzyloxycarbonyl-5-oxo-pyrrolidine-2-carboxylic acid 2-(3-methyl-oxetan-3-yl-methyl) ester 
• 461639-00-9 (2S)-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-5-oxo-pyrrolidine-1-carboxylic acid benzyl ester 
• 531539-25-0 (2S,3S)-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-5-oxo-3-ethyl-pyrrolidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Chemoenzymatic synthesis of glutamic acid analogues: Substrate specificity and synthetic applications of branched chain aminotransferase from Escherichia coli

(Chemical Equation Presented) A new route to α-keto acids is described, based on the ozonolysis of enol acetates obtained from α-substituted β-keto esters. Escherichia coli branched chain aminotransferase (BCAT) activity toward a variety of substituted 2-oxoglutaric acids was demonstrated analytically. BCAT was shown to have a broad substrate spectrum, complementary to that of aspartate aminotransferase, and to offer access to a variety of glutamic acid analogues. The usefulness of BCAT was demonstrated through the synthesis of several 3- and 4-substituted derivatives.

A stereoselective synthesis of 3-substituted (S)-pyroglutamic and glutamic acids via OBO ester derivatives

(S)-Pyroglutamic acid is transformed to the Cbz-protected 4-methyl-2,6,7-trioxabicyclo[2.2.2] octane (OBO) ester. This ortho ester functionality is employed as a bulky steering group for stereoselective introduction of alkyl and aryl groups via 1,4-cuprate addition to 3,4-unsaturated pyroglutamates. After deprotection and ringopening, 3-substituted glutamic acids are obtained.

Heterocyclic sulfonamide inhibitors of beta amyloid production

Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs there